Berrey M Michelle 4
4 · INTERCEPT PHARMACEUTICALS, INC. · Filed Jan 31, 2023
Insider Transaction Report
Form 4
Berrey M Michelle
President, R&D and CMO
Transactions
- Award
Option to Purchase Common Stock
2023-01-27+24,000→ 24,000 totalExercise: $18.40Exp: 2033-01-27→ Common Stock (24,000 underlying) - Award
Common Stock
2023-01-27+14,700→ 83,877 total
Footnotes (2)
- [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2023.
- [F2]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2023.